Updated: Supreme Court to hear Arguments on Outside Salesperson Exemption
1 min read
Apr 16, 2012
Today, the U.S. Supreme Court will hear oral arguments on whether GlaxoSmithKline PLC's offsite and travelling drug sales representatives are entitled to overtime pay. In the past, these representatives have been deemed "exempt" as outside salespeople and not eligible for overtime. Specifically, the Court is presently considering:
The outside sales exemption of the Fair Labor Standards Act exempts from the overtime requirements of the Act "any employee employed ... in the capacity of outside salesman (as such terms are defined and delimited from time to time by regulations of the Secretary ...)." 29 U.S.C. § 213(a)(1). The Secretary of Labor has implemented various regulations that "define and delimit" the outside sales exemption and, filing as amici in this and other related matters, has interpreted these regulations to find the exemption inapplicable to pharmaceutical sales representatives. A split exists between the Second and Ninth Circuits concerning whether this interpretation is owed deference and whether the outside sales exemption of the Fair Labor Standards Act applies to pharmaceutical sales representatives.
The questions presented are:
(1) Whether deference is owed to the Secretary's interpretation of the Fair Labor Standards Act's outside sales exemption and related regulations; and
(2) Whether the Fair Labor Standards Act's outside sales exemption applies to pharmaceutical sales representatives.
The decision in this case could have both significant financial ramifications to the drug industry and will take under consideration how much weight courts must give to regulators' opinions in FLSA disputes.
Improperly classifying employees can prove costly.
Featured Insights

Lawyers' Lawyer Newsletter
Nov 19, 2026
Private Capital and Professional Independence: MSOs and the Changing Business of Law

In The News
Nov 18, 2026
William Schubert: Why Client Confidentiality Reigns Supreme for Motions to Withdraw
![[Byline] Revisiting Disparate Impact Liability Under Executive Order 14281](/a/web/9w8wghM45uReApTZbaaDqe/eFisyR/examining-disparate-impact-liability-in-financial-services-under-executive-order-14281-insights.jpg)
In The News
Nov 18, 2026
[Byline] Revisiting Disparate Impact Liability Under Executive Order 14281

In The News
Nov 17, 2026
Justin Penn Examines FCRA Trends Involving “Legal vs. Factual Inaccuracy” Defense

Consumer Crossroads: Where Financial Services and Litigation Intersect
Nov 16, 2026
SCOTUS to Decide: Are Bankruptcy Stay Violations Arbitrable?

Press Release
Nov 13, 2026
Hinshaw Advises Client Safe Harbor Capital Partners in $44 Million Financing

In The News
Nov 12, 2026
Spencer Kook Authors Article Providing a Claims Manager’s Guide to Class Action Exposure

In The News
Nov 12, 2026
Mitch Chargo Discusses Cannabis M&A Implications in a Post-Rescheduling Landscape

Webinar
Nov 12, 2026
Michael Adams Presents on Navigating Ethics in the Digital Age

Event
Nov 12, 2026
Cathy Mulrow-Peattie Discusses AI and Supply Chain Cybersecurity

Healthcare Alert
Nov 11, 2026
Illinois Enacts 340B Contract Pharmacy Protections: 7 Steps Covered Entities Should Take

